NCT03016533: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 |
|
|
| Completed | 3 | 101 | US, RoW | Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets, ABC/DTG/3TC film-coated dispersible tablets | ViiV Healthcare | HIV Infections | 12/24 | 12/24 | | |
NCT05660980: Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age |
|
|
| Recruiting | 1/2 | 90 | US, RoW | Once daily CAB tablet + RPV tablet, Long acting CAB injectable + long acting RPV injectable | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH) | HIV-1-infection | 08/25 | 07/27 | | |
